en Pharmacokinetics/Dynamics Pharmacokinetics/Dynamics Experimental research article Experimental research article <div style="text-align: justify;"><strong><span class="fontstyle0">Introduction: </span></strong><span class="fontstyle2">Psychomotor slowing and reduced mental flexibility are symptoms of cognitive decline that can occur in type 2 diabetes disease (TD2). Strategies that combine the control of hyperglycaemia with prevention of cognitive decline are desirable. Thus, this study reports the effect of naringin on cognitive deficit in diabetic rats. </span><strong><span class="fontstyle0">Methods: </span></strong><span class="fontstyle2">TD2 in Wistar rats was induced with nicotinamide/streptozotocin (NA/STZ). Naringin (50 and 100 mg/kg) or glibenclamide (5mg/kg) was administered for 30 days to diabetic rats. Cognitive performance was investigated using the Morris water maze. Serum glucose, lipid profiles, brain tumour necrosis factor alpha (TNF-&alpha;) and acetylcholinesterase (AChE) activity were determined. </span><span class="fontstyle0"><strong>Results:</strong> </span><span class="fontstyle2">Naringin and glibenclamide significantly reduced the escape latency, increased the time spent in the correct quadrant and number of entries in diabetic rats. Also, naringin reduced blood glucose, serum cholesterol, low-density lipoprotein cholesterol levels, triglycerides and prevented a decrease in the level of high-density lipoprotein cholesterol, in diabetic rats. Naringin and glibenclamide treated diabetic rats showed a significant low levels of AChE activity and TNF-&alpha;. </span><strong><span class="fontstyle0">Conclusion: </span></strong><span class="fontstyle2">Naringin ameliorates diabetes induced cognitive deficit via reduction of inflammation, hyperglycemia, hyperlipidaemia and AChE activity</span></div> Naringin, Diabetes, Cognitive decline, Inflammation, Acetylcholinesterase. 20 29 http://ppj.phypha.ir/browse.php?a_code=A-10-1374-2&slc_lang=en&sid=1 Abiodun Oyindamola O oo.abiodun@mail.ui.edu.ng 3200319475328460030718 3200319475328460030718 Yes Department of Pharmacology and Therapeutics, College of Medicine, University of Ibadan, Ibadan, Nigeria Bakre Adewale G 3200319475328460030719 3200319475328460030719 No Department of Pharmacology and Therapeutics, College of Medicine, University of Ibadan, Ibadan, Nigeria Adekoya Christiana T 3200319475328460030720 3200319475328460030720 No Department of Pharmacology and Therapeutics, College of Medicine, University of Ibadan, Ibadan, Nigeria Kazeem Adebola I 3200319475328460030721 3200319475328460030721 No Department of Pharmacology and Therapeutics, College of Medicine, University of Ibadan, Ibadan, Nigeria Oke Tolulope A 3200319475328460030722 3200319475328460030722 No Department of Pharmacology and Toxicology, Faculty of Pharmacy, University of Ibadan, Ibadan, Nigeria Ujomu Tejumade S 3200319475328460030723 3200319475328460030723 No Department of Anatomy, Physiology and Pharmacology, Lead City University, Ibadan, Nigeria